Spero Therapeutics, Inc. current report, Q1 FY2019

Full document

Business Context and Reporting Period

Company: Spero Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 4, 2019 (Event Date)
Reporting Period: Specific event reporting for January 2019.
Context: Spero Therapeutics, an emerging growth company, entered into a material definitive agreement to license its product candidate SPR206 in specific Asian territories.

Key Financial Metrics

This filing reports a specific transaction rather than periodic financial statements. Key financial terms of the agreement include:

  • Upfront Payment: $3 million received upon execution of the License Agreement.
  • Potential Milestone Payments: Up to $59.5 million contingent on developmental, regulatory, and sales milestones for SPR206.
  • Royalties: High single-digit to low double-digit percentages on net sales of Licensed Products in the Territory following regulatory approval.
  • Debt and Liquidity: The filing text does not provide a clear value for current debt levels, cash flow, or overall liquidity.
  • Revenue and Margins: The filing text does not provide a clear value for historical revenue or profit margins.

Material Changes

The primary material change is the entry into a License Agreement with Everest Medicines II Limited on January 4, 2019. Key changes include:

  • Geographic Rights: Spero granted Everest an exclusive license to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and certain Southeast Asian countries.
  • Retained Rights: Spero retains global rights outside the Territory and the right to develop/manufacture in the Territory for use outside the Territory.
  • Option Granted: Everest received a 12-month exclusive option to negotiate an exclusive license for Spero's product candidate SPR741 in the Territory.
  • Cost Allocation: Everest assumes all costs for development, regulatory approval, and commercialization within the Territory.

Outlook, Risks, and Contingencies

Management Commentary and Outlook:

  • A joint development committee will be established to coordinate plans.
  • Everest is obligated to use commercially reasonable efforts to achieve specified diligence milestones.
Risks and Contingencies:
  • Milestone Uncertainty: The $59.5 million in potential milestone payments cannot be guaranteed as they depend on future achievements.
  • Termination Rights: Everest may terminate the agreement in its entirety upon 90 or 180 days' prior written notice, depending on the development stage.
  • Regulatory Approval: Royalties are contingent upon regulatory approval of the Compound in the Territory.
  • Confidentiality: Certain portions of the agreement are subject to a Confidential Treatment Request.
Other Events:
  • On January 7, 2019, Spero issued a press release regarding regulatory and clinical updates for product candidate SPR994.

Investor Verification Checklist

  • Verify the receipt of the $3 million upfront payment in the next quarterly financial report (Form 10-Q).
  • Review the full License Agreement (to be filed as an exhibit to the Q1 2019 Form 10-Q) for specific definitions of "milestone events" and royalty tiers.
  • Monitor the status of the 12-month option for SPR741 to determine if Everest exercises the right to negotiate.
  • Assess the impact of Everest's cost assumption on Spero's future cash burn rate for the SPR206 program in the Territory.
  • Review the separate press release (Exhibit 99.2) for details on the clinical progress of SPR994.